Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302

May 14, 2012

by Sophiris Bio News Release

In: Posted Date, Published Date

Article published on November 24, 2011
Samuel Denmeade et al.

Background: PRX302 is a prostate specific antigen (PSA)–activated pore-forming protein toxin under development as a targeted approach for improving lowerurinary tract symptoms (LUTS) caused by

Read more

Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia

Feb 1, 2014

by annica

In: Publications, Uncategorized

Article published April, 2013
Mostafa M. Elhilali et al.

Purpose: We conducted a safety and efficacy evaluation of intraprostatic injection of PRX302, a modified pore forming protein (proaerolysin) activated by prostate specific antigen, as a highly targeted,

Read more